Survival in renal cell carcinoma - A randomized evaluation of tamoxifen vs interleukin 2, α-interferon (leucocyte) and tamoxifen

British Journal of Cancer

Volumn 77, Issue 8, 1998, Pages 1311-1317

  Henriksson, R ^a   Nilsson, S ^b   Colleen, S ^c   Wersall P ^d   Helsing, M ^e   Zimmerman, R ^f   Engman, K ^g  

^a UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d KAROLINSKA INSTITUTE   (Sweden)

^e ÖREBRO MEDICAL CENTRE HOSPITAL   (Sweden)

^f STOCKHOLM SÖDER HOSPITAL   (Sweden)

^g BioNative AB   (Sweden)

Author keywords

Interleukin 2; Renal cell carcinoma; Survival; Tamoxifen; interferon

Indexed keywords

ALPHA INTERFERON A; ANTIESTROGEN; RECOMBINANT INTERLEUKIN 2; TAMOXIFEN;

ADULT; AGED; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG COST; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; INFECTION; KIDNEY CARCINOMA; LIFE EXPECTANCY; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MOUTH DISEASE; MULTICENTER STUDY; MYALGIA; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN DISEASE; SUBCUTANEOUS DRUG ADMINISTRATION; SWEDEN;

EID: 0031935841     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.218     Document Type: Article

References (28)

1. Ahrén B, Engman K and Lindblom A (1992) Treatment of malignant midgut careinoid with a highly purified human leukocyte α-interferon. Anticancer Res 12: 129-134
2. Atzpodien J, Körfer A, Franks CR, Poliwoda H and Kirchner H (1990) Home therapy with recombinant interleukin-2 and interferon-α2b in advanced human malignancies. Lancet 335: 1509-1512
3. Atzpodien J, Hänninen LE, Kirchner M, Bodenstein H, Pfreundschuh M, Rehmann U, Metzner B, Illiger H-J, Jakse G, Niesel T, Scholz H-J, Wilhelm S, Pielmeier T, Zabrewski G, Blum G, Beier J, Müller G-W, Duensing S, Anton P. Allhoff E, Jonas U and Poliwoda H (1995) Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma. J Clin Oncol 13: 497-501
4. Atzpodien J, Kirchner H, Franzke A, Wandert T, Probst M, Buer J, Duensing S and Ganser A (1997) Results of a randomized clinical trial comparing SC interleukin-2, SC alpha-2a-interferon, and IV bolus 5-fluorouracil against oral tamoxifen in progressive metastatic renal cell carcinoma patients (abstract). Proc ASCO 16: 1164
5. Besana C, Borri A, Bucci K, Citterio G, Di Lucca G, Fortis C. Matteucci P, Tognella S. Tresoldi M, Baiocchi C, Landonio G, Ghislandi E and Rugarli C (1994) Treatment of advanced renal cell cancer with sequential intravenous recombinant interleukin-2 and subcutaneous alpha-interferon. Eur J Cancer 30A: 1292-1298
6. Elhilai M, Gleave M, Fradet Y, Davis I, Venner P, Saad F, Klotz L, Sanders C. Bajamonde A and Paton V (1997) Placebo-associated remissions in a multicenter randomized, double blind trial of interferon gamma 1b (rIFN-) for the treatment of metastatic renal cell carcinoma (mRCC) (abstract), Proc ASCO 16: 1187
7. Elson PJ, Witte RS and Trump DL (1988) Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res 48: 7310-7313
8. Facendola G, Locatelli MC, Pizzocaro G, Piva L, Pegoraro C, Bobbio Pallavicini E, Signaioldi A, Meregalli M, Lombaardi F, Beretta GD, Scanzi F, Labianca R and Luporini G (1995) Subcutaneous administration of interleukin 2 and interferon-alpha-2b in advanced renal cell carcinoma: a confirmatory study. Br J Cancer 72: 1531-1535
9. Fosså SD, Martinelli G, Otto U, Schneider G, Wander H, Oberling F, Bauer HW, Achtnicht U and Holdener EE (1992) Recombinant interferon alfa-2a with or without vinblastine in metastatic renal cell carcinoma: Results of a European multi-center phase III study. Ann Oncol 3: 301-305
10. Hänninen LE, Kirchner H and Atzpodien J (1996) Interleukin-2 based home therapy of metastatic renal cell carcinoma: Risks and benefits in 215 consecutive single institution patients. J Urol 155: 19-25
11. Harris DT (1983) Hormonal therapy and chemotherapy of renal carcinoma. Semin Oncol 10: 422-430
12. Katz SE and Schapira HE (1982) Spontaneous regression of genitourinary cancer - an update. J Urol 128: 1-4
13. Kellokumpu-Lehtinen P, Jantunen I, Flander M. Johansson R, Johansson R and Nordman E (1995) Combined interferon and vinblastine treatment in advanced renal cell cancer. Acta Oncol 34: 975-977
14. Kim B, Warnaka P and Konrad C (1990) Tamoxifen potentiates in vivo antitumor activity of interleukin-2. Surgery 108: 139-145
15. Linehan WM, Shipley WJ and Parkinson DR (1989) Cancer of the kidney and ureter. In: Principles and Practice of Oncology, De Vita VT, Hellman S and Rosenberg SA (eds), pp. 279-1005. J B Lippincott: Philadelphia
16. Ljungberg B and Henriksson R (1997) Immunotherapy of renal cell carcinoma. Curr Opinion Urol 7: 252-258
17. Motzer RJ, Schwartz L, Murray Law T, Murphy BA, Hoffman AD, Albino AP, Vlamis V and Nanus DM (1995) Interferon alfa-2a and 13-cis-retinoic acid in renal cell carcinoma: Antitumor activity in a phase II trial and interactions in vitro. J Clin Oncol 13: 1950-1957
18. Oliver RTD (1994) Renal cell cancer: is there long-term survival advantage from cytokine treatment? Eur J Cancer 30A: 1214-1216
19. Oliver RTD, Nethersell ABW and Bottomley JM (1989) Unexplained spontaneous regression and alpha-interferon as treatment for metastatic renal carcinoma. Br J Urol 63: 128-131
20. Osband ME, Lavin PT, Babayan RK, Graham S, Lamm DL, Parker B, Sawezuk I, Ross S and Krane RJ (1990) Effect of autolymphocyte therapy on survival and quality of life in patients with metastatic renal-cell carcinoma. Lancet 335: 994-998
21. Philip T, Negrier S, Lasset C, Coronel B, Bret M, Baly JY, Merrouche Y, Carrie C, Kaemmerlein P, Chauvin F, Favrot M, Oskam R, Tabah I, Clavel M, Moskovtchenko JF and Mercatello A (1993) Patients with metastataic renal carcinoma candidate for immunotherapy with cytokines. Analysis of a single institution study on 181 patients. Br J Cancer 68: 1036-1042
22. Prümmer O (1993) Interferon-alpha antibodies in patients with renal cell carcinoma treated with recombinant interferon-alpha-2A in an adjuvant multicenter trial. Cancer 71: 1828-1834
23. Rosenberg SA, Lotze MT, Yang JC, Topalian SL, Chang AE, Schwartzentruber DJ, Aebersold P, Leitman S, Linehan WM, Seipp CA, White DE and Steinberg SM (1993) Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst 85: 622-632
24. Savage PD (1995) Renal cell carcinoma. Curr Opin Oncol 7: 275-280
25. 0 renal cell carcinoma (abstract). Proc ASCO 16: 1163
26. Stahl M, Schmoll E, Becker H, Schlichter A, Hoffman L, Wagner H, Possinger K, Müller W, Köllermann M, Weidenhammer W and Schmoll H-J (1991) Lopidamine versus high-dose tamoxifen in progressive, advanced renal cell carcinoma: results of an ongoing randomized phase II study. Semin Oncol 18: 33-37
27. Steineck G, Strander H, Carbin B-E, Borgström E, Wallin L, Achtnich U, Arvidsson A, Söderlund V, Näslund I, Esposti P-L and Norell SE (1990) Recombinant leukocyte interferon alpha-2a and medroxyprogesterone in advanced renal cell carcinoma. A randomized trial. Acta Oncol 29: 155-162
28. Wagstaff J, Baars JW, Wolbink G-J, Hoekman K, Eerenberg-Belmer AJM and Hack CE (1995) Renal cell carcinoma and interleukin-2: A review. Eur J Cancer 31A: 401-408